Genocea Biosciences (GNCA) Tops Q4 EPS by 1c

Genocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).

Genocea’s existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15